OncoMatch/Clinical Trials/NCT06667154
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
Is NCT06667154 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Low-dose nivolumab combined with platinum-based doublet chemotherapy for lung cancer, nonsmall cell.
Treatment: Low-dose nivolumab combined with platinum-based doublet chemotherapy — The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
Negative for EGFR gene expression. Positive for EGFR gene expression [excluded].
Required: ALK wild-type
Negative for ALK protein expression. Positive for ALK protein expression [excluded].
Required: ROS1 wild-type
Negative for ROS1 protein expression. Positive for ROS1 protein expression [excluded].
Required: PD-L1 (CD274) expression documented and assessable (documented and assessable)
PD-L1 protein expression documented and assessable. No available data on PD-L1 protein expression [excluded].
Disease stage
Required: Stage IB, II, IIIA
Excluded: Stage IA, IIIB N3, IIIC, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Lab requirements
Blood counts
Hemoglobin: ≥ 9.0 g/dL; Absolute neutrophil count: ≥ 1.5 × 10^9 /L; Platelet count: ≥ 100 × 10^9 /L. G-CSF, platelet transfusions, and blood transfusions are not permitted to meet these values.
Kidney function
Creatinine clearance: ≥ 50 mL/min (calculated using the Cockcroft and Gault formula).
Liver function
Serum bilirubin: ≤ 1.5 × upper limit of normal (ULN), except for participants with confirmed Gilbert syndrome, who may be included upon physician consultation. ALT and AST: ≤ 2.5 × ULN.
Adequate organ and bone marrow function as defined below: Hemoglobin: ≥ 9.0 g/dL; Absolute neutrophil count: ≥ 1.5 × 10^9 /L; Platelet count: ≥ 100 × 10^9 /L; Serum bilirubin: ≤ 1.5 × upper limit of normal (ULN), except for participants with confirmed Gilbert syndrome, who may be included upon physician consultation. ALT and AST: ≤ 2.5 × ULN. Creatinine clearance: ≥ 50 mL/min (calculated using the Cockcroft and Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06667154 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IB or II or IIIA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify